E. Vardas

发表

Beyond the Checklist: Assessing Understanding for HIV Vaccine Trial Participation in South Africa

Cecilia Milford, Michael Quayle, M. Quayle, 2006, Journal of acquired immune deficiency syndromes.

Predicting the Impact of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Low- and Middle-Income Countries: A South African Example

D. Owens, E. Vardas, A. Paltiel, 2007, Journal of acquired immune deficiency syndromes.

The epidemiology of respiratory syncytial virus (RSV) infections in South African children.

E. Vardas, D. Blaauw, J. McAnerney, 1999, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

H. Jessen, A. Giuliano, J. Palefsky, 2011, The New England journal of medicine.

Sequence analysis of the nucleocapsid gene of measles virus isolates from South Africa identifies a new genotype.

E. Vardas, T. Whistler, S. Kreis, 1997, The Journal of general virology.

Coxsackievirus Infections

E. Vardas, 2017 .

The epidemiology and molecular characterstics of hepatitis B virus infection in children from a hyperendemic area of South Africa, including a field trial of the hepatitis B immunization programme and its impact on infection in this population

E. Vardas, 2014 .

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.

H. Jessen, A. Giuliano, J. Palefsky, 2013, Vaccine.

Viral hepatitis in South African healthcare workers at increased risk of occupational exposure to blood-borne viruses.

E. Vardas, J. McAnerney, G. Sharp, 2002, The Journal of hospital infection.

Isolation of measles virus from a naturally-immune, asymptomatically re-infected individual.

E. Vardas, S. Kreis, 1999, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

N. Wolfe, J. Shiver, W. Straus, 2010, Vaccine.

Effect of human immunodeficiency virus infection on episodes of diarrhea among children in South Africa

E. Vardas, J. Frean, O. Perovic, 2000, The Pediatric infectious disease journal.

HIV-1 Tat-based vaccines: from basic science to clinical trials.

M. Magnani, A. Scoglio, S. Moretti, 2002, DNA and cell biology.

Novel mutations identified using a comprehensive CCR5-denaturing gradient gel electrophoresis assay

D. Petersen, V. Hayes, E. Vardas, 2001, AIDS.

The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants.

K. Okita, E. Vardas, K. Hino, 2001, Vaccine.

Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old

H. Jessen, A. Giuliano, J. Palefsky, 2011, Clinical and Vaccine Immunology.

Sexual risk behaviour of the first cohort undergoing screening for enrolment into Phase I/II HIV vaccine trials in South Africa

E. Vardas, G. Gray, L. Niccolai, 2009, International journal of STD & AIDS.

HIV vaccine trials in South Africa--some ethical considerations.

G. Lindegger, C. Slack, E. Vardas, 2000, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Prevalence of hepatitis C virus antibodies and genotypes in asymptomatic, first-time blood donors in Namibia.

F. Sitas, E. Vardas, K. Seidel, 1999, Bulletin of the World Health Organization.

Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States

H. Whittle, Wentao Gao, Huijie Sun, 2004, Clinical Diagnostic Laboratory Immunology.

Preimmunization epidemiology of hepatitis B virus infection in South African children

E. Vardas, D. Blaauw, J. McAnerney, 1999, Journal of medical virology.

GB virus C prevalence in blood donors and high risk groups for parenterally transmitted agents from Gauteng, South Africa†

E. Vardas, D. Blaauw, B. Schoub, 1998, Journal of medical virology.

Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms

M. Grigioni, G. D'Avenio, L. Tavoschi, 2014, PloS one.

Characterization of variable regions of the Gp120 protein from HIV-1 subtype C virus variants obtained from individuals at different disease stages in Sub-Saharan Africa

G. D'Avenio, L. Tavoschi, M. Ciccozzi, 2012 .

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.

M. Colvin, M. Ciccozzi, A. Scoglio, 2003, The Journal of infectious diseases.

Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials

C. Gray, C. Williamson, L. Bekker, 2011, PloS one.

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

G. Pantaleo, A. McMichael, W. Jaoko, 2007, Vaccine.

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

E. Vardas, B. Ensoli, S. Buttò, 2012, Journal of immunological methods.

Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population.

C. Gray, A. Puren, M. Colvin, 2012, Human immunology.

External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents.

H. Jessen, A. Giuliano, J. Palefsky, 2011, The Journal of infectious diseases.

HIV Testing Using Dried Blood Spots

E. Vardas, R. Phili, 2002, Tropical doctor.

Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.

G. Pantaleo, E. Vardas, M. Ustav, 2012, Vaccine.

Cross-Clade Reactivity of HIV-1-Specific T-cell Responses in HIV-1-Infected Individuals From Botswana and Cameroon

D. Burke, N. Wolfe, J. Shiver, 2006, Journal of acquired immune deficiency syndromes.

Preparing for phase II/III HIV vaccine trials in Africa.

M. Clerici, E. Vardas, S. Buttò, 2005, Microbes and infection.

Evaluation of a rapid human immunodeficiency virus test at two community clinics in Kwazulu-Natal.

E. Vardas, R. Phili, 2002, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

The impact of human immunodeficiency virus type 1 status on human papillomavirus (HPV) prevalence and HPV antibodies in serum and cervical secretions.

G. Ramjee, E. Vardas, R. Rose, 2000, The Journal of infectious diseases.

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

H. Jessen, A. Giuliano, J. Palefsky, 2011, Human vaccines.

Characterization of HIV type 1 genetic diversity among South African participants enrolled in the AIDS Vaccine Integrated Project (AVIP) study.

M. Clerici, E. Vardas, B. Ensoli, 2010, AIDS research and human retroviruses.

Case Report and Molecular Analysis of Subacute Sclerosing Panencephalitis in a South African Child

E. Vardas, P. Leary, S. Kreis, 1999, Journal of Clinical Microbiology.

Anticipated changes in sexual risk behaviour following vaccination with a low-efficacy HIV vaccine: survey results from a South African township

E. Vardas, G. Gray, L. Niccolai, 2012, International journal of STD & AIDS.

A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.

Philip R. Johnson, P. Kaleebu, L. Bekker, 2010, AIDS research and human retroviruses.

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events

P. Kaleebu, S. Kochhar, J. van Lunzen, 2012, Human vaccines & immunotherapeutics.